JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akciju saraksts・Simulations Plus Inc

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

14.83 4.66

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.73

Max

14.9

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Dividenžu ienesīgums	0.48
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+7.31% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.48% 2.36%
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	44M 295M
Iepriekšējā atvēršanas cena	10.17
Iepriekšējā slēgšanas cena	14.83

Ziņu noskaņojums

By Acuity

24%

76%

42 / 347 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. maijs 23:47 UTC

Peļņas

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

2026. g. 3. maijs 22:35 UTC

Peļņas

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

2026. g. 3. maijs 23:39 UTC

Tirgus saruna

Gold Edge Higher Amid Signs of Resilience -- Market Talk

2026. g. 3. maijs 23:34 UTC

Tirgus saruna

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

2026. g. 3. maijs 23:32 UTC

Peļņas

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

2026. g. 3. maijs 23:30 UTC

Tirgus saruna

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

2026. g. 3. maijs 23:20 UTC

Tirgus saruna

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

2026. g. 3. maijs 23:16 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

2026. g. 3. maijs 22:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. maijs 22:45 UTC

Tirgus saruna

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

2026. g. 3. maijs 22:20 UTC

Peļņas

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

2026. g. 3. maijs 22:08 UTC

Peļņas

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

2026. g. 3. maijs 22:04 UTC

Peļņas

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

2026. g. 3. maijs 22:03 UTC

Peļņas

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

2026. g. 3. maijs 22:03 UTC

Peļņas

NAB 1H Cash Return on Equity 8.5%>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H Cash Earnings A$2.64B>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

2026. g. 3. maijs 15:06 UTC

Peļņas

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

7.31% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD 7.31%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

42 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Citi krājumi no sektora

JNJ

Johnson and Johnson

227.46

UNH

UnitedHealth Group Inc

369.01

TMO

Thermo Fisher Scientific Inc

469.28

ISRG

Intuitive Surgical Inc

457.59

ABT

Abbott Laboratories

89.51

Live chat